As a young man, Goethe visited Jewish schools in Frankfurt, and even attended a circumcision and a Jewish wedding ...
It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt. An FDA advisory committee ...
Martin Ruegner/Stone/Getty Images (winter landscape); Justin Dodd/Mental Floss (background) “Winter is good,” Emily Dickinson once declared, “But welcome when he goes.” She was so right. The season ...
A town's major shopping centre has reportedly been bought by an investment firm for about £150m. US-based Realty Income bought The Lexicon in Bracknell from previous owners Schroder Capital UK Real ...
Lexicon Pharmaceuticals is positioned for a potential turnaround with three key drug programs and recent partnerships, despite a challenging history. LXRX's sotagliflozin faces uncertain FDA approval ...
Some Dún Laoghaire doors were slammed in canvassing politicians’ faces in advance of the 2014 local elections if they admitted they supported the then yet to open library, according to local ...
THE WOODLANDS, Texas, July 18, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that data from a study of patients describing the impact of diabetic peripheral ...
remove-circle Internet Archive's in-browser bookreader "theater" requires JavaScript to be enabled. It appears your browser does not have it turned on. Please see ...
THE WOODLANDS, Texas — A Houston-area pharmaceutical company has struck a billion-dollar deal with the seller of Ozempic for a potential drug also aiming to combat obesity. Lexicon Pharmaceuticals Inc ...
Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for the preclinical obesity drug LX9851. The company abandoned its underperforming heart failure drug and shifted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback